- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Ramucirumab for liver cancer
Ramucirumab (Cyramza) led to improved overall survival and delayed disease progression in people with hepatocellular carcinoma (HCC), according to study results presented at the American Society of Clinical Oncology (ASCO) annual meeting last month in Chicago.
The REACH-2 study showed that second-line treatment with ramucirumab extended median survival by only about a month compared with placebo. However, the proportion of people who were still alive at 18 months after starting treatment more than doubled, from 11.3% to 24.5%.
Sorafenib (Nexavar) is the standard first-line systemic therapy for advanced HCC, according to recently updated HCC guidelines from the European Association for the Study of the Liver (EASL). The guidelines also recommend lenvatinib (Lenvima). Regorafenib (Stivarga) is recommended for second-line treatment, and cabozantinib (Cabometyx) has shown good results in clinical trials. Although EASL does not yet recommend immunotherapy for liver cancer, the US Food and Drug Administration has approved the checkpoint inhibitor nivolumab (Opdivo) for HCC.
Ramucirumab (Cyramza) is a monoclonal antibody that interferes with angiogenesis, or blood vessel formation. By blocking activation of vascular endothelial growth factor receptor 2 (VEGFR2), the drug prevents the development of new blood vessels needed to supply growing tumours.
Related links
Read "Ramucirumab targeted therapy extends liver cancer survival" on infohep.org
|
|